Pharmacokinetics of mifepristone after low oral doses

Contraception

Volumn 54, Issue 4, 1996, Pages 229-234

  Kekkonen, Raimo ^a   Heikinheimo, Oskari ^a   Mandelin, Erik ^a   Lähteenmäki, Pekka ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

antiprogestin RU 486; individual variability; multiple doses; radioimmunoassay; single dose

Indexed keywords

MIFEPRISTONE;

ADULT; ARTICLE; CONTRACEPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG USE; FEMALE; HUMAN; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PREGNANCY TERMINATION;

EID: 0030273725     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(96)00193-X     Document Type: Article

References (31)

1. 1. World Health Organization. Pregnancy termination with mifepristone (RU 486) and gemeprost: a multicentre comparison between repeated doses and a single dose of mifepristone. Fertil Steril 1991;6:32-40.
2. 2. World Health Organization. Termination of pregnancy with reduced doses of mifepristone. BMJ 1993;307: 532-7.
3. 3. Bertagna X, Bertagna C, Luton J-P, Husson J-M, Girard F. The new steroid analog RU 486 inhibits glucocorticoid action in man. J Clin Endocrinol Metab 1984;59: 25-8.
4. 4. Garrel DR, Moussali R, Oliveira AD, Lesiège D, Larivière F. RU 486 prevents the acute effects of cortisol on glucose and leucin metabolism. J Clin Endocrinol Metab 1995;80:379-85.
5. 5. Luukkainen T, Heikinheimo O, Haukkamaa M, Lähteenmäki P. Inhibition of folliculogenesis and ovulation by the antiprogesterone RU 486. Fertil Steril 1988; 49:961-3.
6. 6. Ledger WL, Sweeting VM, Hillier H, Baird DT. Inhibition of ovulation by low-dose mifepristone (RU 486). Human Reprod 1992;7:945-50.
7. 7. Croxatto HB, Salvatierra AM, Croxatto HD, Fuentealba B. Effects of continuous treatment with low dose mifepristone throughout one menstrual cycle. Human Reprod 1993;8:201-7.
8. 8. Kekkonen R, Lähteenmäki P. Cyclic progestin administration brings about luteinization during continuous antiprogestin treatment. Contraception 1996;53:193-5.
9. 9. Cameron ST, Thong KJ, Baird DT. Effect of daily low dose mifepristone on the ovarian cycle and on dynamics of follicle growth. Clin Endocrinol 1995;43:407-14.
10. 10. Batista MC, Cartledge TP, Zellmer AW, Nieman LK, Merriam GR, Loriaux DL. Evidence for a critical role of progesterone in the regulation of the midcycle gonadotropin surge and ovulation. J Clin Endocrinol Metab 1992;74:565-70.
11. 11. Batista MC, Cartledge TP, Zellmer AW, Nieman LK, Loriaux DL, Merriam GR. The antiprogestin RU486 delays the midcycle gonadotropin surge and ovulation in gonadotropin-releasing hormone-induced cycles. Fertil Steril 1994;62:28-34.
12. 12. Murphy AA, Morales AJ, Kettel LM, Yen SSC. Regression of uterine leiomyomata to the antiprogesterone RU 486: dose-response effect. Fertil Steril 1995;64:187-90.
13. 13. Murphy AA, Kettel LM, Morales AJ, Roberts V, Farmley T, Yen SSC. Endometrial effects of long-term low-dose administration of RU 486. Fertil Steril 1995;63: 761-6.
14. 14. Batista MC, Cartledge TP, Zellmer AW et al. Delayed endometrial maturation induced by daily administration of the antiprogestin RU 486: A potential new contraceptive strategy. Am J Obstet Gynecol 1992;167:60-5.
15. 15. Glasier A, Thong KJ, Dewar M, Mackie M, Baird DT. Postcoital contraception with mifepristone. Lancet 1991;337:1414-5.
16. 16. Glasier A, Thong KJ, Dewar M, Mackie M, Baird DT. Mifepristone (RU 486) compared with high-dose estrogen and progestogen for emergency postcoital contraception. N Engl J Med 1992;327:1041-4.
17. 17. Heikinheimo O, Tevilin M, Shoupe D, Croxatto H, Lähteenmäki P. Quantitation of RU 486 in human plasma by HPLC and RIA after column chromatography. Contraception 1986;34:613-24.
18. 18. Rowland M, Tozer TN. Clinical pharmacokinetics. Concepts and applications. 2nd ed. Philadelphia and London:Lea and Febiger, 1989:459-63.
19. 19. Rowland M, Tozer TN. Clinical pharmacokinetics. Concepts and applications. 2nd ed. Philadelphia and London:Lea and Febiger, 1989:469-72
20. 20. Heikinheimo O, Lähteenmäki PLA, Koivunen E et al. Metabolism and serum binding of RU 486 in women after various single doses. Human Reprod 1987;2:379-85.
21. 21. Heikinheimo O, Kontula K, Croxatto H, Spitz I, Luukkainen T, Lähteenmäki P. Plasma concentrations and receptor binding of RU 486 and its metabolites in humans. J Steroid Biochem 1987;26:279-84.
22. 22. Wang JD, Shi WL, Zhang GQ, Bai XM. Tissue and serum levels of steroid hormones and RU 486 after administration of mifepristone. Contraception 1994;49: 245-53.
23. 23. Shi YE, Ye ZH, He CH et al. Pharmacokinetic study of RU 486 and its metabolites after oral administration of single doses to pregnant and non-pregnant women. Contraception 1993;48:133-49.
24. 24. Philibert D, Moguilevski M, Bonnat C, Busigny M, Pottier J. Influence of human alpha-1-acid glycoprotein (AAG) on pharmacokinetics and biological activity of RU 486. In: Abstracts of the 68th Meeting of the Endocrine Society, Anaheim, CA; Abstract 1006, Bethesda, MD:The Endocrine Society 1986:282.
25. 25. Heikinheimo O. Pharmacokinetics of the antiprogesterone RU 486 in women during multiple dose administration. J Steroid Biochem 1989;32:21-5.
26. 26. Spitz IM, Heikinheimo O, Wade CE. The divergent effect of RU 486 on adrenal function in the dog is related to differences in its pharmacokinetics. Acta Endocrinol 1993;128:459-65.
27. 27. Jacqs-Aigrain E, Panserat S, Sica L, Krishnamoorthy R. Molecular genetics of cytochrome P-450 IID. Clin Rev Allerg Immunol 1995;13:211-21.
28. 28. Spatzenegger M, Jaeger W. Clinical importance of hepatic cytochrome P-450 in drug metabolism. Drug Metab Rev 1995;27:397-417.
29. 29. Heikinheimo O, Kekkonen R. Dose-response relationships of RU 486. Ann Med 1993;25:71-6.
30. 30. Deraedt R, Bonnat C, Busigny M et al. Pharmacokinetics of RU 486. In: Baulieu EE, Segal SJ, eds. The antiprogestin steroid RU 486 and human fertility control. New York:Plenum Press, 1985:103-22.
31. 31. Swahn ML, Cekan S, Wang G, Lundström V, Bygdeman M. Pharmacokinetic and clinical studies of RU 486 for fertility regulation. In: Baulieu EE, Segal SJ, eds. The antiprogestin steroid RU 486 and human fertility control. New York:Plenum Press, 1985:249-58.